United States securities and exchange commission logo





                             May 17, 2021

       Purnanand D. Sarma, Ph.D.
       President and Chief Executive Officer
       Immunome, Inc.
       665 Stockton Drive, Suite 300
       Exton, PA 19341

                                                        Re: Immunome, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed May 11, 2021
                                                            File No. 333-256018

       Dear Dr. Sarma:

              We have limited our review of your registration statement to
those issues we have
       addressed in our comments. In some of our comments, we may ask you to
provide us with
       information so we may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-1

       Selling Stockholders, page 6

   1.                                                   We note the statement
on the cover page of the prospectus that selling stockholders will be
                                                        named in the prospectus
or in supplements to the prospectus. Please note that since you
                                                        are not eligible to
rely on Rule 430B of Regulation C, you must file a post-effective
                                                        amendment to add
selling stockholders to the registration statement. Please revise your
                                                        disclosure as
appropriate and include the amount of securities registered on behalf of each
                                                        selling shareholder.
For guidance, please refer to Rule 430B and Regulation S-K CD&I
                                                        140.03.
 Purnanand D. Sarma, Ph.D.
FirstName
Immunome,LastNamePurnanand D. Sarma, Ph.D.
            Inc.
Comapany
May        NameImmunome, Inc.
     17, 2021
May 17,
Page 2 2021 Page 2
FirstName LastName
Incorporation of Certain Documents by Reference, page 14

2.       Please update the documents incorporated by reference to include the
quarterly report on
         Form 10-Q for the quarter ended March 31, 2021.

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Chris Edwards at 202-551-6761 or Celeste Murphy at
202-551-3257 with
any questions.



                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Life
Sciences
cc:      Daniel A. Bagliebter, Esq.